Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior

European Journal of Pharmacology

Volumn 730, Issue 1, 2014, Pages 157-163

  Hodgson, Robert A ^a   Mullins, Deborra ^a   Lu, Sherry X ^a   Guzzi, Mario ^a   Zhang, Xiaoping ^a   Bleickardt, Carina J ^a   Scott, Jack D ^a   Miller, Michael W ^a   Stamford, Andrew W ^a   Parker, Eric M ^a   Varty, Geoffrey B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Anxiety; Depression; Mouse; Rat; Vasopressin

Indexed keywords

CHLORDIAZEPOXIDE; IMIPRAMINE; UNCLASSIFIED DRUG; V1B 30N; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1B RECEPTOR; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; VASOPRESSIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG POTENCY; DRUG STRUCTURE; FEMALE; FORCED SWIM TEST; GUINEA PIG MODEL; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; TRANQUILIZING ACTIVITY; TREATMENT OUTCOME; VOCALIZATION; ANIMAL; ANIMAL BEHAVIOR; ANXIETY; CONDITIONING; DRUG EFFECTS; DRUG THERAPY; GUINEA PIG; METABOLISM; MOUSE; SWIMMING;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; ANXIETY; BEHAVIOR, ANIMAL; CONDITIONING (PSYCHOLOGY); DEPRESSION; FEMALE; GUINEA PIGS; MALE; MICE; RATS; RECEPTORS, VASOPRESSIN; SWIMMING; VOCALIZATION, ANIMAL;

EID: 84896573337     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.02.027     Document Type: Article

References (33)

1. R. Alonso, G. Griebel, G. Pavone, J. Stemmelin, G. Le Fur, and P. Soubrie Blockade of CRF(1) or V(1b) receptors reversed stress-induced suppression of neurogenesis in a mouse model of depression Mol. Psychiatry 9 2004 278 286
2. A.V. Amikishieva, S.I. Ilnitskaya, V.P. Nikolin, and N.A. Popova Effect of vasopressin V1b receptor antagonist, SSR149415, on anxiety-like behavior and Lewis lung carcinoma metastasis in mice Exp. Oncol. 3 2011 126 129
3. E. Appenrodt, R. Schnabel, and H. Schwarzberg Vasopressin administration modulates anxiety-related behavior in rats Physiol. Behav. 64 1998 543 547
4. E. Appenrodt, and H. Schwarzberg Central vasopressin administration failed to influence anxiety behavior after pinealectomy in rats Physiol. Behav. 68 2000 735 739
5. C.J. Bleickardt, D.E. Mullins, C.P. MacSweeney, B.J. Werner, A.J. Pond, M.F. Guzzi, F.D. Martin, G.B. Varty, and R.A. Hodgson Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior Psychopharmacology 202 2009 711 718
6. M.E. Breuer, M.M. van Gaalen, W. Wernet, S.E. Claessens, R.S. Oosting, B. Behl, S.M. Korte, H. Schoemaker, G. Gross, B. Olivier, and L. Groenink SSR149415, a non-peptide vasopressin V1b receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model Naunyn Schmiedebergs Arch. Pharmacol. 379 2009 101 106
7. Y. Cheng, and W.H. Prusoff Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 22 1973 3099 3108
8. M. Craighead, R. Milne, L. Campbell-Wan, L. Watson, J. Presland, F.J. Thomson, H.M. Marston, and C.P. Macsweeney Characterization of a novel and selective V1B receptor antagonist Prog. Brain Res. 170 2008 527 535
9. T. Dassanayake, P. Michie1, G. Carter, and A. Jones Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence Drug Saf. 34 2012 125 156
10. G. Griebel, J. Simiand, C. Serradeil-Le Gal, J. Wagnon, M. Pascal, B. Scatton, J.P. Maffrand, and P. Soubrie Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders Proc. Natl. Acad. Sci. USA 30 2002 6370 6375
11. R.A. Hodgson, D. Guthrie, A. Pond, C. Morgan, X. Lu, D. Mullins, M. Miller, A. Stamford, M. Guzzi, and Varty G. Parker Characterization of a Novel Nonselective V1a/b Antagonist (SCH 756491) in Animal Models of Anxiety-like Behavior, 828.6. Neuroscience Meeting Planner 2006 Society for Neuroscience Atlanta, GA.
12. R.A. Hodgson, D.H. Guthrie, and G.B. Varty Duration of ultrasonic vocalizations in the isolated rat pup as a behavioral measure: sensitivity to anxiolytic and antidepressant drugs Pharmacol Biochem Behav 88 2008 341 348
13. R.A. Hodgson, G.A. Higgins, D.H. Guthrie, S.X. Lu, A.J. Pond, D.E. Mullins, M.F. Guzzi, E.M. Parker, and G.B. Varty Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression Pharmacol. Biochem. Behav. 86 2007 431 440
14. M. Iijima, and S. Chaki Separation-induced ultrasonic vocalization in rat pups: further pharmacological characterization Pharmacol Biochem Behav 82 2005 652 657
15. M. Iijima, and S. Chaki An arginine vasopressin V1b antagonist, SSR149415 elicits antidepressant-like effects in an olfactory bulbectomy model Prog. Neuropsychopharmacol. Biol. Psychiatry 31 2007 622 627
16. J.H. Kehne The CRF1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders CNS Neurol. Disord. Drug Targets 6 2007 163 182
17. K.S. Kendler, R.E. Weitzman, and D.A. Fisher The effect of pain on plasma arginine vasopressin concentrations in man Clin. Endocrinol. 8 1978 89 94
18. E.J. Lin Neuropeptides as therapeutic targets in anxiety disorders Curr. Pharm. Des. 18 2012 5709 5727
19. S.X. Lu, G.A. Higgins, R.A. Hodgson, L.A. Hyde, R.A. Del Vecchio, D.H. Guthrie, T.M. Kazdoba, M.F. McCool, C.A. Morgan, A. Bercovivi, G.D. Ho, D. Tulshian, E.M. Parker, J.C. Hunter, and G.B. Varty The anxiolytic-like profile of the nociceptin NOP receptor agonist, endo-8-[bis(2-chlorophenyl)methyl]-3- phenyl-8-azabicyclo[3.2.1]octane-3-carboxamide (SCH 655842): Comparison of efficacy and side-effects across rodent species Eur. J. Pharmacol. 661 2011 63 71
20. A. Maillet, H.C. Gunga, G. Gauquelin, J.O. Fortrat, A. Hope, L. Røcker, K. Kirsch, and C. Gharib Effects of 28-day isolation (ESA-ISEMSI 90) on blood pressure and blood volume regulating hormones Aviat Space Environ. Med. 64 1993 287 294
21. J.L. Meyerhoff, M.A. Oleshansky, K.T. Kalogeras, E.H. Mougey, G.P. Chrousos, and L.G. Granger Neuroendocrine responses to emotional stress: possible interactions between circulating factors and anterior pituitary hormone release Adv. Exp. Med. Biol. 274 1990 91 111
22. S.E. Napier, J.J. Letourneau, N. Ansari, D.S. Auld, J. Baker, S. Best, L. Campbell-Wan, J.H. Chan, M. Craighead, H. Desai, K.A. Goan, K.K. Ho, E.G. Hulskotte, C.P. MacSweeney, R. Milne, J.R. Morphy, I. Neagu, M.H. Ohlmeyer, A.W. Peeters, J. Presland, C. Riviello, G.S. Ruigt, F.J. Thomson, H.A. Zanetakos, J. Zhao, and M.L. Webb Synthesis and SAR studies of novel 2-(4-oxo-2-aryl- quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists Bioorg. Med. Chem. Lett. 21 2011 1871 1875
23. D.H. Overstreet, and G. Griebel Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat Pharmacol. Biochem. Behav. 83 2005 223 227
24. J.S. Purba, W.J. Hoogendijk, M.A. Hofman, and D.F. Swaab Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression Arch. Gen. Psychiatry 53 1996 137 143
25. M.M. Savić, S. Huang, R. Furtmüller, T. Clayton, S. Huck, D. Obradović, N.D. Ugrešić, W. Sieghart, D.R. Bokonjić, and J.M. Cook Are GABAA receptors containing α5 subunits contributing to the sedative properties of benzodiazepine site agonists? Neuropsychopharmacology 33 2008 332 339
26. HO. Schild pAx and competitive drug antagonism Br. J. Pharmacol. 4 1949 277 280
27. J.D. Scott, M.W. Miller, S.W. Li, S.I. Lin, H.A. Vaccaro, L. Hong, D.E. Mullins, M. Guzzi, J. Weinstein, R.A. Hodgson, G.B. Varty, A.W. Stamford, T.Y. Chan, B.A. McKittrick, W.J. Greenlee, T. Priestley, and E.M. Parker Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists Bioorg. Med. Chem. Lett. 19 2009 6018 6022
28. C. Serradeil-Le Gal, J. Wagnon, J. Simiand, G. Griebel, C. Lacour, G. Guillon, C. Barberis, G. Brossard, P. Soubrie, D. Nisato, M. Pascal, R. Pruss, B. Scatton, J.P. Maffrand, and G. Le Fur Characterization of (2S, 4R)-[5 Chgloro-1-[(2,4-dimethoxyphenyl) sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3- dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J. Pharmacol. Exp. Ther. 300 2002 1122 1130
29. C. Serradeil-Le Gal, J. Wagnon, B. Tonnerre, R. Roux, G. Garcia, G. Griebel, and A. Aulombard An overview of SSR149415, a selective nonpeptide vasopressin V1b receptor antagonist for the treatment of stress related disorders CNS Drug Rev. 11 2005 53 68
30. A. Tanoue, S. Ito, K. Honda, S. Oshikawa, S. Kitagawa, T. Koshimizu, T. Mori, and G. Tsujimoto The vasopressin V1b receptor critically regulates hypothalamic- pituitary-adrenal axis activity under both stress and resting conditions J. Clin. Invest. 113 2004 302 309
31. L. van Londen, J.G. Goekoop, G.M. van Kempen, A.C. Frankhuijzen- Sierevogel, V.M. Wiegant, E.A. van der Velde, and D. De Wied Plasma levels of arginine vasopressin elevated in patients with major depression Neuropsychopharmacology 17 1997 284 292
32. G.B. Varty, M. Grilli, A. Forlani, S. Fredduzzi, M.E. Grzelak, D.H. Guthrie, R.A. Hodgson, S.X. Lu, E. Nicolussi, A.J. Pond, E.M. Parker, J.C. Hunter, G.A. Higgins, A. Reggiani, and R. Bertorelli The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: A comparison of efficacy and side-effect profiles Pharmacology 2005 207 217
33. G.B. Varty, L.A. Hyde, R.A. Hodgson, S.X. Lu, M.F. McCool, T.M. Kazdoba, R.A. Del Vecchio, D.H. Guthrie, A.J. Pond, M.E. Grzelak, X. Xu, W.A. Korfmacher, D. Tulshian, E.M. Parker, and G.A. Higgins Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species Psychopharmacology 2005 132 143